Developer docs
API playgroundTry for free, no card

Search company profiles

Deep Intelligent Pharma

Full company profile

uuid00046s6

Namestring
Deep Intelligent Pharma
Legal namestring
Deep Intelligent Particle (Beijing) Technology Co., Ltd.
Websiteurl
dip-ai.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Deep Intelligent Pharma (DIP) is a Singapore-headquartered AI company that provides an integrated clinical research and drug discovery platform for pharmaceutical, biotechnology, and material science companies across China, Japan, and the United States. Founded in 2017 by AI scientists from global pharma giants, DIP operates three core AI products — AI CRO 6.0 (clinical research platform with tens of thousands of bionic workers running 24/7), Molecule Design Engine (mechanism-driven drug discovery platform), and Agent Matrix (multi-agent orchestration deployed since 2023) — plus a Protocol Rehearsal virtual clinical trials product launched in February 2026. The underlying technology integrates large-scale AI models with scientific computing to automate protocol design, data capture, biostatistics, medical writing, and regulatory submissions across NMPA, FDA, and PMDA jurisdictions, with reported performance gains of 12x in protocol design, 50x in clinical operations monitoring, and 15x in medical writing.

The company monetizes through enterprise B2B subscriptions and professional services, offering AI CRO full-stack solutions spanning preclinical research, clinical trials, and post-marketing research on a quote-based annual billing model. Its go-to-market is consultative direct enterprise sales targeting pharmaceutical companies, biotech firms, and material science enterprises across seven application domains (agrochemicals, batteries, semiconductors, alloys, polymers, high-standard metals, chemical materials). DIP has accumulated 1,000+ signed clients globally, achieved a stated 16% market share in the global LLM and agent-driven clinical CRO market per a 2026 Frost & Sullivan certification, and secured a zero-defect PMDA consultation pass (Immunorock) demonstrating regulatory execution. The company claims sustained profitability since 2021 and reached unicorn status at a multi-billion dollar valuation following a $50 million Series D in December 2025, followed by $60 million in February 2026 and $40 million in March 2026 — totaling $150 million raised within three months from investors including CDH Baifu/HongShan Capital, Trustar Capital, Xinding Capital, Jinyi Capital, Kaitai Capital, ZhenFund, and CITIC Capital.

Short descriptiontext

Deep Intelligent Pharma is a Singapore-based AI company that provides an AI-powered clinical trial and drug discovery platform for global pharmaceutical, biotech, and material science companies, automating protocol design, clinical operations, and regulatory submissions through a proprietary multi-agent ecosystem.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBeijing, China
HQ citystring
Beijing
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI clinical trials, drug discovery platform, clinical research software, multi-agent orchestration, pharmaceutical R&D AI
Industry3 codes
PRIMARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHDAEANAA
End-to-End Enterprise AI Platforms (MLOps & Model Lifecycle Management)
Hardware, Technology & Telecom/Enterprise Platforms & Databases/Artificial Intelligence Platforms for Enterprise
NAICS code2 codes
  • Software Publishers5132
  • Custom Computer Programming Services541511
SIC code2 codes
  • Services-Prepackaged Software7372
  • Services-Computer Integrated Systems Design7373
Product category
AI Clinical Trial Software
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1AI CRO Services
TypeSubscription Recurring
Description

Full-stack AI solutions for pharmaceutical companies covering preclinical research, clinical trials, and post-marketing research through subscription and usage-based engagement

dipgroup.com
2Technology Platform Licensing
TypeSubscription Recurring
Description

Providing AI-powered core technology systems as foundational pharmaceutical infrastructure to enterprise clients

vcbeatglobal.com
3Professional Services
TypeProfessional Services
Description

Consulting and implementation services for AI-driven drug discovery and clinical trial optimization

vcbeatglobal.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Enterprise solutions with custom pricing based on scope and engagement model
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based pricing for enterprise AI CRO solutions

dipgroup.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1AI CRO 6.0
Description

Clinical Research Platform with tens of thousands of bionic workers running 24x7 to accelerate pipeline development.

dipgroup.com
+2 more records
Core offering1 text field

Deep Intelligent Pharma builds AI-powered software platforms for pharmaceutical and biotech companies, integrating large-scale AI models with scientific computing across the drug development lifecycle. Its three core products — AI CRO 6.0 (clinical research platform), Molecule Design Engine (drug discovery), and Agent Matrix (multi-agent orchestration) — automate protocol design, clinical operations, data capture, biostatistics, regulatory submissions, and medical writing for pharmaceutical, biotech, and material science clients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 12x acceleration in protocol design (from 3 months to 1 week)
+5 more records
Product overview1 text field

Deep Intelligent Pharma operates a unified platform architecture with three core AI products: AI CRO 6.0 (clinical research platform), Molecule Design Engine (drug discovery platform), and Agent Matrix (multi-agent orchestration). These products work together as an integrated system, with Agent Matrix enabling autonomous orchestration of workflows across the clinical research and molecule design platforms. The company also offers Protocol Rehearsal as a virtual clinical trials capability. The platform serves both life sciences (drug development) and material science (batteries, semiconductors, agrochemicals) markets, providing end-to-end AI solutions from preclinical research through post-marketing studies.

Product and service4 records
1AI CRO 6.0
CategoryClinical Research Platform
Description

Clinical research platform for pharmaceutical and biotech companies providing AI-assisted protocol design, intelligent data capture with real-time paperless workflows, AI-driven biostatistics and biomarker analysis, and automated CSR authoring. Targets enterprise pharma and biotech clients seeking to compress clinical timelines and reduce CRO manpower dependency.

2Molecule Design Engine
CategoryDrug Discovery Platform
Description

Drug discovery platform using mechanism-driven AI simulation to enable precision targeting, compressing molecular screening to candidate confirmation from years to weeks. Designed for pharmaceutical R&D teams seeking AI-driven molecular design with deep understanding of biological mechanisms.

3Agent Matrix
CategoryMulti-Agent Orchestration Platform
Description

Multi-agent orchestration platform enabling matrix deployment of six agents collaborating in parallel 24x7 since 2023 for autonomous drug discovery and development workflows. Enables human-AI collaboration in life sciences and serves as the orchestration backbone for the company's other products.

4Protocol Rehearsal
CategoryVirtual Clinical Trials Simulation
Description

Virtual clinical trials product that conducts simulated clinical trials to predict enrollment outcomes before real patient enrollment, helping clinical teams de-risk protocol design and enrollment planning.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven drug discovery and clinical development platform combining generative AI, multi-omics, and automated labs; directly comparable as an AI-native pharma R&D company serving pharma/biotech customers with similar end-to-end drug discovery and clinical workflows.

TypeDirect peer
Description

AI-native biotech combining high-throughput wet-lab experimentation with machine learning for drug discovery; comparable in the AI-for-drug-development category and competes for similar pharma/biotech customers and partnerships.

TypeDirect peer
Description

AI-driven drug discovery and materials science platform combining quantum physics, AI, and high-performance computing; closely comparable given dual life-sciences and materials-science focus and Asia-Pacific origin.

TypeDirect peer
Description

Physics-based computational chemistry and AI platform for molecular design and drug discovery serving global pharma; comparable as an enterprise software platform replacing traditional CRO/drug discovery workflows with AI-accelerated computation.

TypeEmerging player
Description

AI-driven small molecule discovery platform using convolutional neural networks for hit identification; comparable in AI-driven drug discovery but with narrower focus on early-stage hit finding versus DIP's end-to-end clinical trial coverage.

TypeBroad incumbent
Description

Enterprise clinical trial technology platform providing EDC, CTMS, eCOA and analytics to pharma/biotech; comparable as a clinical trial informatics vendor but embedded in much broader Dassault Systèmes 3DEXPERIENCE platform.

TypeBroad incumbent
Description

Largest global CRO with embedded AI/analytics capabilities across clinical operations, real-world evidence, and commercial; competes for the same enterprise pharma customers but as a broad incumbent rather than AI-native specialist.

TypeBroad incumbent
Description

Top-tier global CRO providing full-service clinical development with growing AI/data capabilities; comparable as a clinical CRO serving enterprise pharma, but with traditional labor-based delivery model rather than agent-driven execution.

TypeEmerging player
Description

AI-driven drug discovery company using knowledge graphs and ML to identify novel targets and drug candidates; comparable in AI drug discovery category but focused on target identification rather than end-to-end clinical trial execution.

TypeOthers
Description

Enterprise cloud software platform serving life sciences with CTMS, EDC, regulatory, and quality applications; adjacent peer as a software platform that pharma/biotech customers use to manage clinical trials, sharing the same buyer base as DIP.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Deep Intelligent Pharma

AI Clinical Trial Softwaredip-ai.com

Deep Intelligent Pharma is a Singapore-based AI company that provides an AI-powered clinical trial and drug discovery platform for global pharmaceutical, biotech, and material science companies, automating protocol design, clinical operations, and regulatory submissions through a proprietary multi-agent ecosystem.

What Deep Intelligent Pharma does

Deep Intelligent Pharma (DIP) is a Singapore-headquartered AI company that provides an integrated clinical research and drug discovery platform for pharmaceutical, biotechnology, and material science companies across China, Japan, and the United States. Founded in 2017 by AI scientists from global pharma giants, DIP operates three core AI products — AI CRO 6.0 (clinical research platform with tens of thousands of bionic workers running 24/7), Molecule Design Engine (mechanism-driven drug discovery platform), and Agent Matrix (multi-agent orchestration deployed since 2023) — plus a Protocol Rehearsal virtual clinical trials product launched in February 2026. The underlying technology integrates large-scale AI models with scientific computing to automate protocol design, data capture, biostatistics, medical writing, and regulatory submissions across NMPA, FDA, and PMDA jurisdictions, with reported performance gains of 12x in protocol design, 50x in clinical operations monitoring, and 15x in medical writing.

The company monetizes through enterprise B2B subscriptions and professional services, offering AI CRO full-stack solutions spanning preclinical research, clinical trials, and post-marketing research on a quote-based annual billing model. Its go-to-market is consultative direct enterprise sales targeting pharmaceutical companies, biotech firms, and material science enterprises across seven application domains (agrochemicals, batteries, semiconductors, alloys, polymers, high-standard metals, chemical materials). DIP has accumulated 1,000+ signed clients globally, achieved a stated 16% market share in the global LLM and agent-driven clinical CRO market per a 2026 Frost & Sullivan certification, and secured a zero-defect PMDA consultation pass (Immunorock) demonstrating regulatory execution. The company claims sustained profitability since 2021 and reached unicorn status at a multi-billion dollar valuation following a $50 million Series D in December 2025, followed by $60 million in February 2026 and $40 million in March 2026 — totaling $150 million raised within three months from investors including CDH Baifu/HongShan Capital, Trustar Capital, Xinding Capital, Jinyi Capital, Kaitai Capital, ZhenFund, and CITIC Capital.

Deep Intelligent Pharma firmographics

Firmographics
Name
Deep Intelligent Pharma
Legal name
Deep Intelligent Particle (Beijing) Technology Co., Ltd.
Website
https://dip-ai.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Deep Intelligent Pharma is a Singapore-based AI company that provides an AI-powered clinical trial and drug discovery platform for global pharmaceutical, biotech, and material science companies, automating protocol design, clinical operations, and regulatory submissions through a proprietary multi-agent ecosystem.
Ownership category
akta.pro rank

Deep Intelligent Pharma industry classification

Industry
Product category
AI Clinical Trial Software
NAICS
Software Publishers (5132), Custom Computer Programming Services (541511)
SIC
Services-Prepackaged Software (7372), Services-Computer Integrated Systems Design (7373)
akta.pro industry
PRIMARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHDAEANAA
End-to-End Enterprise AI Platforms (MLOps & Model Lifecycle Management)
Hardware, Technology & Telecom/Enterprise Platforms & Databases/Artificial Intelligence Platforms for Enterprise

Keywords

  • AI clinical trials
  • Drug discovery platform
  • Clinical research software
  • Multi-agent orchestration
  • Pharmaceutical R&D AI

Where Deep Intelligent Pharma is headquartered

Location

Headquarters

HQ city
Beijing
HQ country
China
HQ region
Asia

Offices3 records

Markets served

Deep Intelligent Pharma business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. AI CRO Services: Full-stack AI solutions for pharmaceutical companies covering preclinical research, clinical trials, and post-marketing research through subscription and usage-based engagement
  2. Technology Platform Licensing: Providing AI-powered core technology systems as foundational pharmaceutical infrastructure to enterprise clients
  3. Professional Services: Consulting and implementation services for AI-driven drug discovery and clinical trial optimization

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise solutions with custom pricing based on scope and engagement model

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Deep Intelligent Pharma product offering

Product offering

Core offering

Deep Intelligent Pharma builds AI-powered software platforms for pharmaceutical and biotech companies, integrating large-scale AI models with scientific computing across the drug development lifecycle. Its three core products — AI CRO 6.0 (clinical research platform), Molecule Design Engine (drug discovery), and Agent Matrix (multi-agent orchestration) — automate protocol design, clinical operations, data capture, biostatistics, regulatory submissions, and medical writing for pharmaceutical, biotech, and material science clients.

Product overview

Deep Intelligent Pharma operates a unified platform architecture with three core AI products: AI CRO 6.0 (clinical research platform), Molecule Design Engine (drug discovery platform), and Agent Matrix (multi-agent orchestration). These products work together as an integrated system, with Agent Matrix enabling autonomous orchestration of workflows across the clinical research and molecule design platforms. The company also offers Protocol Rehearsal as a virtual clinical trials capability. The platform serves both life sciences (drug development) and material science (batteries, semiconductors, agrochemicals) markets, providing end-to-end AI solutions from preclinical research through post-marketing studies.

Differentiator

Problem solved

Functional benefit

Brands

  • AI CRO 6.0: Clinical Research Platform with tens of thousands of bionic workers running 24x7 to accelerate pipeline development.
  • Molecule Design Engine
  • Agent Matrix

Products and services

  • AI CRO 6.0 Clinical research platform for pharmaceutical and biotech companies providing AI-assisted protocol design, intelligent data capture with real-time paperless workflows, AI-driven biostatistics and biomarker analysis, and automated CSR authoring. Targets enterprise pharma and biotech clients seeking to compress clinical timelines and reduce CRO manpower dependency.
  • Molecule Design Engine Drug discovery platform using mechanism-driven AI simulation to enable precision targeting, compressing molecular screening to candidate confirmation from years to weeks. Designed for pharmaceutical R&D teams seeking AI-driven molecular design with deep understanding of biological mechanisms.
  • Agent Matrix Multi-agent orchestration platform enabling matrix deployment of six agents collaborating in parallel 24x7 since 2023 for autonomous drug discovery and development workflows. Enables human-AI collaboration in life sciences and serves as the orchestration backbone for the company's other products.
  • Protocol Rehearsal Virtual clinical trials product that conducts simulated clinical trials to predict enrollment outcomes before real patient enrollment, helping clinical teams de-risk protocol design and enrollment planning.

Quantifiable outcome

  • 12x acceleration in protocol design (from 3 months to 1 week)
  • +5 more outcomes

Companies that use Deep Intelligent Pharma

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Deep Intelligent Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature5 records

Deep Intelligent Pharma partnerships and signals

Strategic signal

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Deep Intelligent Pharma competitors and assessment

Company assessment

Direct peers

  • Insilico Medicine: AI-driven drug discovery and clinical development platform combining generative AI, multi-omics, and automated labs; directly comparable as an AI-native pharma R&D company serving pharma/biotech customers with similar end-to-end drug discovery and clinical workflows.
  • Recursion Pharmaceuticals: AI-native biotech combining high-throughput wet-lab experimentation with machine learning for drug discovery; comparable in the AI-for-drug-development category and competes for similar pharma/biotech customers and partnerships.
  • XtalPi: AI-driven drug discovery and materials science platform combining quantum physics, AI, and high-performance computing; closely comparable given dual life-sciences and materials-science focus and Asia-Pacific origin.
  • Schrödinger: Physics-based computational chemistry and AI platform for molecular design and drug discovery serving global pharma; comparable as an enterprise software platform replacing traditional CRO/drug discovery workflows with AI-accelerated computation.

Emerging players

  • Atomwise: AI-driven small molecule discovery platform using convolutional neural networks for hit identification; comparable in AI-driven drug discovery but with narrower focus on early-stage hit finding versus DIP's end-to-end clinical trial coverage.
  • BenevolentAI: AI-driven drug discovery company using knowledge graphs and ML to identify novel targets and drug candidates; comparable in AI drug discovery category but focused on target identification rather than end-to-end clinical trial execution.

Broad incumbents

  • Medidata (Dassault Systèmes): Enterprise clinical trial technology platform providing EDC, CTMS, eCOA and analytics to pharma/biotech; comparable as a clinical trial informatics vendor but embedded in much broader Dassault Systèmes 3DEXPERIENCE platform.
  • IQVIA: Largest global CRO with embedded AI/analytics capabilities across clinical operations, real-world evidence, and commercial; competes for the same enterprise pharma customers but as a broad incumbent rather than AI-native specialist.
  • ICON plc: Top-tier global CRO providing full-service clinical development with growing AI/data capabilities; comparable as a clinical CRO serving enterprise pharma, but with traditional labor-based delivery model rather than agent-driven execution.

Others

  • Veeva Systems: Enterprise cloud software platform serving life sciences with CTMS, EDC, regulatory, and quality applications; adjacent peer as a software platform that pharma/biotech customers use to manage clinical trials, sharing the same buyer base as DIP.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Deep Intelligent Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Deep Intelligent Pharma leadership team

Management profile

Number of profiles

Profiles2 records

Deep Intelligent Pharma funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Deep Intelligent Pharma M&A and investment

M&A and investment

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Deep Intelligent Pharma

What does Deep Intelligent Pharma do?

Deep Intelligent Pharma builds AI-powered software platforms for pharmaceutical and biotech companies, integrating large-scale AI models with scientific computing across the drug development lifecycle. Its three core products — AI CRO 6.0 (clinical research platform), Molecule Design Engine (drug discovery), and Agent Matrix (multi-agent orchestration) — automate protocol design, clinical operations, data capture, biostatistics, regulatory submissions, and medical writing for pharmaceutical, biotech, and material science clients.

Is Deep Intelligent Pharma a public or private company?

Deep Intelligent Pharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was Deep Intelligent Pharma founded?

Deep Intelligent Pharma was founded in 2017. It employs 11 to 50 people.

Where is Deep Intelligent Pharma based?

Deep Intelligent Pharma is headquartered in Beijing, China, in the Asia region.

How does Deep Intelligent Pharma make money?

Three revenue lines are on record. AI CRO Services are the primary driver. The others are technology Platform Licensing and professional Services.

Who are Deep Intelligent Pharma's main competitors?

Direct peers on record are Insilico Medicine, Recursion Pharmaceuticals, XtalPi and Schrödinger. Emerging players are Atomwise and BenevolentAI. Broad incumbents are Medidata (Dassault Systèmes), IQVIA and ICON plc. Veeva Systems is listed as an others.

Does Deep Intelligent Pharma have an API?

No public API is recorded for Deep Intelligent Pharma.

What industry is Deep Intelligent Pharma in?

Deep Intelligent Pharma's product category is AI Clinical Trial Software. Its primary akta.pro industry code is HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageDeep Intelligent Pharma Advances AI for Materials Science and Advanced Material DiscoveryDeep Intelligent Pharma (DIP) is advancing its AI platform for materials science, enabling faster discovery and optimization of advanced materials across various sectors including batteries and semiconductors. The company's technology reportedly accelerates traditional research processes, making material screening 100 to 1,000 times faster than conventional methods. DIP aims to continue expanding its applications and capabilities in materials discovery and AI-guided design.TechBullionDeep Intelligent Pharma Raises $40M; CDH Baifu, Xinding, Jinyi & Kaitai Capital Double DownSingapore-based AI unicorn Deep Intelligent Pharma (DIP) completed a $40 million financing round backed by existing investors CDH Baifu, Xinding Capital, Jinyi Capital, and Kaitai Capital, with Index Capital serving as exclusive financial advisor. Within three months, the company has raised a total of $150 million across multiple funding rounds, reflecting strong investor confidence in its AI-driven dual-engine strategy spanning life sciences and materials science. The capital will be deployed toward developing multi-matrix brain-inspired AGI models, accelerating global expansion to China, Japan, and the United States, and recruiting top-tier talent at the intersection of AI and scientific research.TechBullionBuilding AGI for Pharmaceutical Industry, Deep Intelligent Pharma Secures Another US$60 Million in FundingDeep Intelligent Pharma, an AI-focused pharmaceutical company, has raised an additional US$60 million in funding, bringing total recent funding to over US$100 million. The company develops AI solutions for all stages of drug development, including virtual clinical trials and autonomous agents that improve efficiency and regulatory compliance.FinancialContent Business PageBuilding AGI for Pharmaceutical Industry, Deep Intelligent Pharma Secures Another US$60 Million in FundingAI pharmaceutical-development company Deep Intelligent Pharma completed a US$60 million financing round with new investors Trustar Capital, Jinyi Capital, and Kaitai Capital, while existing shareholders CDH Investments and Xinding Capital increased their stakes. The funding comes less than two months after a US$50 million Series D, bringing the company's total raised capital to over US$100 million within two months. The company plans to use the proceeds to upgrade its core technology systems, which provide end-to-end AI solutions for pharmaceutical development from pre-clinical research through post-marketing studies.openPR.comBuilding AGI for the Pharmaceutical Industry, Deep Intelligent Pharma Secures Another US$60 Million in FundingAI pharmaceutical company Deep Intelligent Pharma has completed a US$60 million financing round with participation from new investors Trustar Capital, Jinyi Capital, and Kaitai Capital, while existing shareholders CDH Investments and Xinding Capital increased their stakes, bringing its total fundraising to over US$100 million in less than two months. The funds will be used to upgrade the company's core technology systems, specifically its AI platform that provides end-to-end intelligent solutions for pharmaceutical development covering pre-clinical research through post-marketing studies. The company has launched a new product called Protocol Rehearsal that conducts virtual clinical trials to predict enrollment outcomes before real patient enrollment.PedailyIn two months, Deep Intelligence has completed a new round of financing of 60 million US dollars.AI pharmaceutical company Deep Intelligence has completed a $60 million financing round with new investors Xincheng Capital, Jinyi Capital, and Kaitai Capital, while existing shareholders Dinghui Baifu and New Ding Capital increased their stakes. The company had previously raised $50 million in Series D financing just two months prior, bringing its total recent fundraising to over $100 million. The funds will be used to upgrade Deep Intelligence's core technology system, which provides AI-powered full-stack solutions for pharmaceutical companies covering preclinical research, clinical trials, and post-marketing research.VcbeatglobalDeep Intelligent Pharma (DIP) secures US$60M in new funding to advance its transition into pharmaceutical infrastructure and promote the democratization of AI technology-VCBeatDeep Intelligent Pharma (DIP), an AI-powered biotech unicorn, announced completion of a US$60 million financing round led by Trustar Capital, Jinyi Capital, and Kaitai Capital, with continued participation from existing shareholders CDH Investments and Xinding Capital. The proceeds will fund a generational upgrade of DIP's core technology system as the company positions itself as foundational pharmaceutical infrastructure, building on its proprietary Synaptic Agent Ecosystem for autonomous drug discovery and development. Index Capital served as the exclusive financial advisor for this transaction.BioXconomyDeep Intelligent Pharma gets $50M for AI trialsSingapore-based Deep Intelligent Pharma (DIP) has secured $50 million in a Series D funding round led by CDH Baifu, with participation from existing investors Xinding Capital and HongShan Capital, to further develop its AI-powered autonomous clinical trial system. The company breaks clinical development into 10,000 high-precision "atomic agents" and claims its technology achieves 99.9% industrial-grade accuracy, citing Japanese cancer vaccine developer Immunorock as an example where the system helped pass PMDA review in a single submission with zero revisions. DIP intends to use the funds to support iterative development of its platform and expand its global commercialization network.DealStreetAsiaHongShan-backed GenAI startup DIP raises nearly $50m Series D fundingDeep Intelligent Pharma (DIP), a Chinese generative AI startup focused on pharmaceutical and medtech innovation, raised nearly $50 million in a Series D funding round led by Dinghui Baifu. The funds will support its global expansion and AI solution R&D, targeting increased adoption among Chinese pharma and biotech companies involved in international drug registration and clinical trials.PedailyDeep Intelligence (DIP) completes nearly $50 million Series D financing, led by Dinghui Baifu.Deep Intelligent Pharma (DIP) announced the completion of nearly $50 million in Series D financing, led by Dinghui Baifu with participation from existing shareholders New Ding Capital and Sequoia China, and Index Capital serving as exclusive financial advisor. The funds will be used to advance a fully automated clinical system and expand a global commercialization network, marking the company's transition from AI-assisted tools to decision-making infrastructure in drug development. The company has built a multi-agent ecosystem combining over 10,000 atomized agents capable of end-to-end clinical trial automation, including protocol design, patient screening simulation, and regulatory submission.